olaparib trial summary

All type of patients: 1 trials - OlympiAD

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	0.90 [0.63 1.29]	p=1.00	0	302	1	OlympiAD,
progression or death (progression free survival PFS)	0.58 [0.43 0.79]	p=0.04	0	302	1	OlympiAD,
treatment discontinuation due to toxic effects	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

BRCA-mutated: 1 trials - OlympiAD

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	0.90 [0.63 1.29]	p=1.00	0	302	1	OlympiAD,
progression or death (progression free survival PFS)	0.58 [0.43 0.79]	p=0.04	0	302	1	OlympiAD,
treatment discontinuation due to toxic effects	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

HER 2 negative : 1 trials - OlympiAD

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	0.90 [0.63 1.29]	p=1.00	0	302	1	OlympiAD,
progression or death (progression free survival PFS)	0.58 [0.43 0.79]	p=0.04	0	302	1	OlympiAD,
treatment discontinuation due to toxic effects	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patient (BRCA mutated or not): 2 trials - Ledermann - SOLO2/ENGOT-Ov21

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	no data
progression or death (progression free survival PFS)	0.30 [0.22 0.41]	p=0.04	0	295	1	SOLO2/ENGOT-Ov21,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	0.94 [0.63 1.40]	p=1.00	0	265	1	Ledermann,
progression or death (progression free survival PFS)	0.35 [0.25 0.49]	p=0.04	0	265	1	Ledermann,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with BRCA mutation: 1 trials - SOLO2/ENGOT-Ov21

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
death (overall survival)	no data
progression or death (progression free survival PFS)	0.30 [0.22 0.41]	p=0.04	0	295	1	SOLO2/ENGOT-Ov21,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Olaparib poly ADP-ribose polymerase (PARP) inhibitor